Logo

American Heart Association

  1
  0


Final ID: TP324

Lupus Anticoagulant Is Associated With Acute Recurrence in Cardiogenic Embolic Stroke in Older Patients

Abstract Body: Background and Purpose: Antiphospholipid antibody syndrome (APS) is a rare cause of cerebral infarction, but the effect of antiphospholipid antibodies (aPL) on the acute phase of ischemic stroke in each stroke subtypes is still unclear, especially in the elderly patients. To clarify this, we compared antiphospholipid antibody levels in patients with acute cerebral infarction with or without recurrence, expansion, or hemorrhagic transformation of infarct in each stroke subtype.
Methods: Consecutive ischemic stroke patients in a comprehensive stroke center were screened between April 2013 and April 2024. Inclusion criteria were: 1) admitted 24 hours from the onset, 2) more than 60 years-old on the admission, 3) who had follow-up MRI/CT around one week from the onset, and 4) whose aPL (anti-cardiolipin-beta2-glycoprotein I complex antibody [β2-GPI], anti-cardiolipin antibody [aCL] and lupus anticoagulant [LAC]) measured during the admission for suspected APS. Then, we dichotomized the patients with and without recurrence (R), expansion (E), or hemorrhagic transformation (HT) of infarct upon follow-up MRI/CT findings. We compared clinical features including aPL between the groups by each stroke subtypes based on TOAST classification. Sensitivity and specificity were calculated from receiver operating characteristic (ROC) curve of aPL for predicting R, E, and HT.
Results: We screened 2,528 consecutive ischemic stroke patients and 271 patients met the inclusion criteria (60 [22%] cardioembolism (CE), 43 [16%] large-artery atherosclerosis, 29 [11%] small-vessel occlusion and 139 [51%] others). In enrolled patients, 30 (11%) patients showed R, 43 (16%) patients for E and 65 (24%) patients for HT. In CE, CL aCL and LAC were higher in patients with R compared without R (aCL 9.5 vs. 8.0 U/mL, p=0.047; LAC 1.15 vs. 1.01, p=0.006) while aPL were not significantly different in other stroke subtypes. Also, aPL were not significantly different between the patients with and without E or HT. In CE, R increased as LAC became higher (1st tertile vs. 2nd tertile vs. 3rd tertile of LAC: 0 (0%) vs. 1 (6%) vs. 6 (33%), p=0.004). In ROC analysis, the optimal cutoff of LAC for predicting R in CE was 1.12 (area under curve 0.83 [95% confidence interval 0.71-0.94], p=0.006; sensitivity 0.86, specificity 0.82).
Conclusions: In CE, LAC was associated with acute recurrence of infarct. LAC should be measured in cardioembolic stroke with recurrence in acute phase.
  • Kida, Hiroyuki  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Iguchi, Yasuyuki  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Sakai, Kenichiro  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Komatsu, Teppei  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Okumura, Motohiro  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Nakada, Ryoji  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Kitagawa, Tomomichi  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Takatsu, Hiroki  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Sakuta, Kenichi  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Mitsumura, Hidetaka  ( The Jikei University School of Medicine , Tokyo , Japan )
  • Author Disclosures:
    Hiroyuki Kida: DO NOT have relevant financial relationships | Yasuyuki Iguchi: DO have relevant financial relationships ; Speaker:Daiichi-Sankyo:Active (exists now) ; Speaker:Alexion:Active (exists now) ; Speaker:Amagen Biogen:Active (exists now) ; Speaker:Takeda:Active (exists now) ; Speaker:Sumitomo Dainippon:Active (exists now) ; Speaker:Pfizer:Active (exists now) ; Speaker:Otsuka:Active (exists now) ; Speaker:Novartis:Active (exists now) ; Speaker:Mitsubishi-Tanabe:Active (exists now) ; Speaker:JB:Active (exists now) ; Speaker:Eisai:Active (exists now) ; Speaker:CSL-Behring:Active (exists now) ; Speaker:Chugai:Active (exists now) | Kenichiro Sakai: DO NOT have relevant financial relationships | Teppei Komatsu: DO NOT have relevant financial relationships | Motohiro Okumura: DO NOT have relevant financial relationships | Ryoji Nakada: DO NOT have relevant financial relationships | Tomomichi Kitagawa: DO NOT have relevant financial relationships | Hiroki Takatsu: DO NOT have relevant financial relationships | Kenichi Sakuta: DO NOT have relevant financial relationships | Hidetaka Mitsumura: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Risk Factors and Prevention Posters II

Thursday, 02/06/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
A First-in-Class Humanized Antibody Fragment Targeting Platelet Glycoprotein Ibα: A Comprehensive Preclinical Study of CA1001 for the Treatment of Acute Ischemic Stroke

Xu Xiaohong, Preeti Preeti, Yu Ruoying, Shaykhalishahi Hamed, Zhang Cheng, Shen Chuanbin, Li Bei, Tang Naping, Chang Yan, Xiang Qian, Cui Yimin, Lei Xi, Ni Heyu, Zhu Guangheng, Liu Zhenze, Hu Xudong, Slavkovic Sladjana, Neves Miguel, Ma Wenjing, Xie Huifang

A Randomized, Double Blinded, Phase 2B Clinical Trial to Compare the Safety and Efficacy of Sodium Chloride and Sodium Acetate Combination Intravenous Fluids in Acute Stroke Patients

Wasay Muhammad, Suri Fareed, Saleem Shafaq, Qureshi Adnan

More abstracts from these authors:
Small Vessel Disease is Associated With Primary Aldosteronism in Acute Ischemic Stroke

Okumura Motohiro, Komatsu Teppei, Sakuta Kenichi, Sakai Kenichiro, Mitsumura Hidetaka, Nishimura Rimei, Iguchi Yasuyuki, Sato Takeo, Tsujimoto Yuki, Yamashiro Kenji, Watanabe Yui, Kida Hiroyuki, Nakada Ryoji, Kitagawa Tomomichi, Takatsu Hiroki

Multimodal MRI sequences are vital for the diagnosis of Vertebrobasilar Artery Dissection

Nakayama Yoshitaka, Mitsumura Hidetaka, Iguchi Yasuyuki, Kida Hiroyuki, Maku Takahiro, Nakada Ryoji, Kitagawa Tomomichi, Takatsu Hiroki, Komatsu Teppei, Sakuta Kenichi, Sakai Kenichiro

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)